Pomanda estimates the enterprise value of BEACON THERAPEUTICS HOLDINGS LIMITED at £253.8k based on a Turnover of £226.3k and 1.12x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of BEACON THERAPEUTICS HOLDINGS LIMITED at £0 based on an EBITDA of £-47.1m and a 4.47x industry multiple (adjusted for size and gross margin).
Pomanda estimates the enterprise value of BEACON THERAPEUTICS HOLDINGS LIMITED at £33m based on Net Assets of £20.7m and 1.59x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Beacon Therapeutics Holdings LimitedOverview
Beacon Therapeutics Holdings Limited is a live company located in london, N7 9AS with a Companies House number of 14303840. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in August 2022, it's largest shareholder is
syncona portfolio limited
with a 58.5% stake. Beacon Therapeutics Holdings Limited is a startup,
micro sized company, Pomanda has estimated its turnover at
£226.3k with
unknown
growth in recent years.
Pomanda's financial health check has awarded Beacon Therapeutics Holdings Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs
Health Rating2out of 5
3 Strong
1 Regular
5 Weak
Size
annual sales of £226.3k, make it smaller than the average company (£4.5m)
£226.3k - Beacon Therapeutics Holdings Limited
£4.5m - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- - Beacon Therapeutics Holdings Limited
- - Industry AVG
Production
with a gross margin of 53.9%, this company has a comparable cost of product (53.9%)
53.9% - Beacon Therapeutics Holdings Limited
53.9% - Industry AVG
Profitability
an operating margin of -22166.2% make it less profitable than the average company (-4.1%)
-22166.2% - Beacon Therapeutics Holdings Limited
-4.1% - Industry AVG
Employees
with 88 employees, this is above the industry average (54)
88 - Beacon Therapeutics Holdings Limited
54 - Industry AVG
Pay Structure
on an average salary of £221.8k, the company has a higher pay structure (£83k)
£221.8k - Beacon Therapeutics Holdings Limited
£83k - Industry AVG
Efficiency
resulting in sales per employee of £2.6k, this is less efficient (£131.4k)
£2.6k - Beacon Therapeutics Holdings Limited
£131.4k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon Therapeutics Holdings Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 4821 days, this is slower than average (60 days)
4821 days - Beacon Therapeutics Holdings Limited
60 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Beacon Therapeutics Holdings Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 67 weeks, this is more cash available to meet short term requirements (30 weeks)
67 weeks - Beacon Therapeutics Holdings Limited
30 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 70.3%, this is a higher level of debt than the average (53.1%)
70.3% - Beacon Therapeutics Holdings Limited
53.1% - Industry AVG
BEACON THERAPEUTICS HOLDINGS LIMITED financials
EXPORT
Beacon Therapeutics Holdings Limited's latest turnover from December 2023 is £226.3 thousand and the company has net assets of £20.7 million. According to their latest financial statements, Beacon Therapeutics Holdings Limited has 88 employees and maintains cash reserves of £12.2 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Dec 2023
Turnover
226,289
Other Income Or Grants
Cost Of Sales
104,400
Gross Profit
121,888
Admin Expenses
50,281,498
Operating Profit
-50,159,610
Interest Payable
919,083
Interest Receivable
221,088
Pre-Tax Profit
-50,857,604
Tax
1,229,200
Profit After Tax
-49,628,404
Dividends Paid
Retained Profit
-49,628,404
Employee Costs
19,518,492
Number Of Employees
88
EBITDA*
-47,057,042
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023
Tangible Assets
19,066,124
Intangible Assets
24,319,975
Investments & Other
5,704,812
Debtors (Due After 1 year)
596,130
Total Fixed Assets
49,687,042
Stock & work in progress
Trade Debtors
Group Debtors
Misc Debtors
3,669,676
Cash
12,169,668
misc current assets
4,146,631
total current assets
19,985,976
total assets
69,673,018
Bank overdraft
Bank loan
Trade Creditors
1,379,179
Group/Directors Accounts
other short term finances
hp & lease commitments
1,563,444
other current liabilities
6,476,402
total current liabilities
9,419,026
loans
hp & lease commitments
13,947,466
Accruals and Deferred Income
other liabilities
25,583,698
provisions
total long term liabilities
39,531,165
total liabilities
48,950,191
net assets
20,722,827
total shareholders funds
20,722,827
Dec 2023
Operating Activities
Operating Profit
-50,159,610
Depreciation
1,177,047
Amortisation
1,925,521
Tax
1,229,200
Stock
Debtors
4,265,806
Creditors
1,379,179
Accruals and Deferred Income
6,476,402
Deferred Taxes & Provisions
Cash flow from operations
-42,238,067
Investing Activities
capital expenditure
Change in Investments
5,704,812
cash flow from investments
-5,704,812
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
15,510,910
other long term liabilities
25,583,698
share issue
70,351,231
interest
-697,995
cash flow from financing
110,747,844
cash and cash equivalents
cash
12,169,668
overdraft
change in cash
12,169,668
beacon therapeutics holdings limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for beacon therapeutics holdings limited. Get real-time insights into beacon therapeutics holdings limited's credit score, group structure and payment trends.
Perform a competitor analysis for beacon therapeutics holdings limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in N 7 area or any other competitors across 12 key performance metrics.
beacon therapeutics holdings limited Ownership
BEACON THERAPEUTICS HOLDINGS LIMITED group structure
Beacon Therapeutics Holdings Limited has 1 subsidiary company.
The largest shareholders in Beacon Therapeutics Holdings Limited include Syncona Portfolio Limited and Oxford Science Enterprises Plc.
syncona portfolio limited
58.54%
oxford science enterprises plc
13.94%
forbion ventures fund vi coopeatief ua
6.85%
forbion growth opportunities ii fund cooperatief ua
6.85%
tcg crossover fund ii lp
4.41%
advent life science fund ii lp
2.09%
forcal investment fund cv
1.96%
university of oxford
1.26%
robert maclaren
1.24%
advent-harrington impact fund lp
0.76%
beacon therapeutics holdings limited directors
Beacon Therapeutics Holdings Limited currently has 9 directors.
The longest serving directors include
Dr Elisa Petris (Aug 2022) and
Dr Christopher Hollowood (Aug 2022).
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to beacon therapeutics holdings limited.
beacon therapeutics holdings limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BEACON THERAPEUTICS HOLDINGS LIMITED. This can take several minutes, an email will notify you when this has completed.
beacon therapeutics holdings limitedCompanies House Filings - See Documents
